Maternal Serum Screening

Pricing ARUP Client Services (800) 522-2787
Genetic Counselors Danielle LaGrave, MS, LCGC

Danielle LaGrave, M.S., L.C.G.C.,Danielle LaGrave, MS, LCGC, Genetic Counselor
Danielle LaGrave is a genetic counselor with ARUP's Maternal Serum Screening program and Cytogenetics Department. She is certified by the American Board of Genetic Counseling, is licensed by the state of Utah, and is a member of the National Society of Genetic Counselors and the American Society of Human Genetics. Ms. LaGrave received her MS in genetic counseling from California State University, Northridge, and has been a practicing genetic counselor since 1996.

(800) 242-2787, ext. 2020
Kim Hart , MS, LGC (800) 242-2787, ext. 2141
Tanya Tvrdik , MS, LGC (800) 242-2787, ext. 2119
  (STAT recalculations, interpretation, or ordering instructions)
Laboratory Director Edward R. Ashwood, MD

Edward R. Ashwood, MD
President and CEO

Dr. Ashwood is the president and chief executive officer at ARUP and a professor of pathology at the University of Utah School of Medicine. Dr. Ashwood joined ARUP in 1985. He received his MD from the University of Colorado and completed a laboratory medicine residency in clinical pathology at the University of Washington. He is board certified in clinical and chemical pathology, and his research interests include the clinical chemistry of pregnancy. He is co-editor of the Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Tietz Fundamentals of Clinical Chemistry, and Fundamentals of Molecular Diagnostics.

 

 

Patient Information Downloads
Maternal Serum Screening: Choices for Expectant Parents
Maternal Serum Screening: Choices for Expectant Parents (Spanish)
Maternal Serum Triple Screen
Triple Estudio del Suero Maternal
Maternal Serum Quadruple Screen
Cuadruple de Suero Maternal
Maternal Serum Screening: The Integrated Test
Prueba de Suero Materno: Una Prueba Integrada
Maternal Serum Screening: First Trimester Screening
Prueba de Suero Materno en el Primer Trimestre
First-Trimester Screening ARUP Technical Bulletins
*Sonographer providing NT measurement must be certified by FASTER trial, NTQR (SMFM), or FMF. Please contact genetic counselor prior to sending first sample to ensure acceptability.  
0081150 * First Trimester Screen PAPP-A, hCG, and nuchal translucency (NT) measurement
Combined First- and Second-Trimester Screening
*Sonographer providing NT measurement must be certified by FASTER trial, NTQR (SMFM), or FMF. Please contact genetic counselor prior to sending first sample to ensure acceptability.
0081062 * Integrated Screen, Specimen #1 PAPP-A, nuchal translucency (NT) measurement; risk result provided after specimen #2.
Serum-only integrated testing is available if NT measurement cannot be obtained or if sonographer is not NT certified.
0081064 Integrated Screen, Specimen #2 Alpha Fetoprotein, hCG, Estriol, and Inhibin A; combined risk result for specimens #1 and #2
0081293 * Sequential Screen, Specimen #1 PAPP-A, nuchal translucency (NT) measurement
Interpretation—Abnormal: Pregnancy is at ≥1 in 25 risk of Down syndrome or ≥ 1 in 100 for trisomy 18; diagnostic testing and genetic counseling should be offered. Negative: Down syndrome risk does not exceed 1 in 25; trisomy 18 risk does not exceed 1 in 100; specimen #2 should be drawn.
0081294 Sequential Screen, Specimen #2 Alpha Fetoprotein, hCG, Estriol, and Inhibin A; results combined with specimen #1 to provide final risk.  
Second-Trimester Screening
0080108 Triple Screen Alpha Fetoprotein, hCG, and Estriol 
0080269 Quad Screen Alpha Fetoprotein, hCG, Estriol, and Inhibin A
0080434 Alpha Fetoprotein Only AFP only; after first trimester screening or CVS
0080427 AFP (Amniotic Fluid) with Reflex to Acetylcholinesterase
 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org